A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 127
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : bDMARD
Long Form : biological disease-modifying antirheumatic drug
No. Year Title Co-occurring Abbreviation
2022 After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries. AE, CDAI, JAKi, RA
2022 Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study. AS
2022 Antibody response in patients with autoimmune inflammatory rheumatic disease after pneumococcal polysaccharide prime vaccination or revaccination. AIIRD, MTX
2022 Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. CDAI, CKD, CRP, OR, RA
2022 Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal. PsA, RA, Reuma.pt, SpA
2022 Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. EMF, LDA, MEMS, MPR, RA
2022 Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry. RA
2022 Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. IXE
2022 Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial. RA
10  2022 Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. axSpA, BASDAI, WPAI
11  2022 Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology. ABA, cs, HR, RA, RTX, TCZ, TNFi
12  2022 Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study). CDAI, csDMARD, DAS28-ESR, EULAR, JAK, RA, SDAI
13  2022 Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case-control study. DAS28-ESR, HZ, JAKis, RA
14  2022 Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. csDMARDs, PS, RA
15  2022 Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis. ASCVD, CLC, RA
16  2022 Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study. DAS28 ESR, IL-6, IL-6R, RA
17  2022 Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. ICI, IL-6R, JAKi, RA
18  2022 [Axial spondyloarthritis : Update on management based on the interdisciplinary S3 guidelines on axial spondyloarthritis including early forms and ankylosing spondylitis]. NSAID
19  2021 A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. ---
20  2021 Anti-TNF Therapy and the Risk of Malignancies and Infections in Inflammatory Rheumatic Diseases - Our Experience. AS, csDMARD, IR, JIA, PsA, RA, SpA, USpA
21  2021 Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis. JAKi, PRFs, RA, TNFi, ts
22  2021 Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. DDD
23  2021 Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis. ASAS, ASDAS, LOAS, MI, YOAS
24  2021 Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. ABA, RA, RTX, TCZ, TNFi
25  2021 Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort. IL-17, IMIDs, PCR, RRs
26  2021 Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. csCMARD, RA
27  2021 Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry. AS, ES, ESR, IBD, PS
28  2021 ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. CTD
29  2021 Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. ASAS, BASDAI, r-axSpA, TNFi
30  2021 Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. COVID-19, OR, RA
31  2021 Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset. AS, ETN, GOL, OPAL
32  2021 Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. PsA
33  2021 Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. ABA, MOAs, RA, RTX, TCZ, TNFi
34  2021 Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan. RA, TNFi
35  2021 The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis. cDMARD, Non-TNFi, RA, SAT, TNFi
36  2021 The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study. ANCOVA, ASAS, axSpA, HRQoL, MP, NcP, PDQ
37  2021 Tofacitinib versus tocilizumab in the treatment of biological-naive or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis. CDAI, MTX, RA
38  2021 [Methotrexate treatment before use of biologics in rheumatoid arthritis : Analysis of guideline compliance]. MTX, RA
39  2020 Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register. CI, EULAR, HAQ, HR, RA
40  2020 Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network. ABA, CRP, OR, ORA, RA
41  2020 Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. csDMARDs, DSP, MOA, RA, TNFi, tsDMARD
42  2020 Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians. cs, RA, TNFi
43  2020 Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target. CDAI, CREDIT, DAS28, LDA, OR, RA, REM
44  2020 Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BSC, NHS, PsARC, QALY
45  2020 Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. BSC, CEAs, IL-17A, PsA, PsARC, QALYs
46  2020 Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis. ACR, DREAM, ESR, EULAR, RA
47  2020 Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. BPHS, ICUR, RA
48  2020 Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. MTX, PsA
49  2020 Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. ACEIs, ARBs, RMDs, SAH
50  2020 Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). ---
51  2020 Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study. HCP, PsA
52  2020 Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. csDMARDs, ETA, MTX, RA
54  2020 Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. ABA, IFN, RA, RT-qPCR
55  2020 Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. DAS28-CRP, RA, TNFis
56  2020 Is fibromyalgia frequency increasing in axial spondyloarthritis? Association with fibromyalgia and biological therapies. ASDAS, axSpA, BASDAI, FM, VAS
57  2020 Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. ADA, EQ-5D-5L, IXE, PBO, r-axSpA, TNFi
58  2020 Predictors of long-term clinical remission in rheumatoid arthritis. HRs, MST, MTX, RA, SDAI
59  2020 Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic. RA, s.c
60  2020 Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan. CI, DAS28-ESR, HAQ-DI, OR, RA
61  2020 The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. ABA, csDMARD, CVD, GC, MTX, RA, TNFi
62  2020 Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. RA
63  2019 Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept. RA, TNFi
64  2019 Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis. ACPAs, CCP, HCRU, RA
65  2019 Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. ABA, CHF, MI, NMA, PAD, RCT, RTX, TCZ, TNFi
66  2019 Choice of the most appropriate biological disease-modifying anti-rheumatic drug for injection spacing: results from a multicentre observational study. ABT, DIV, GOL, LDA, RA, SC, TCZ, TNF
67  2019 Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. ESR, MTX, RA, RAPID3
68  2019 Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. csDMARDs, DAS28-CRP, RA
69  2019 Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). ASAS40, PBO, r-axSpA, TNFi
70  2019 Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI). csDMARDs, OBRI, RA, s.c, TNFi
71  2019 Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India. ARDs, cs, TB
72  2019 Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis. BCRP, MAF, MDR, MRP
73  2019 Real-world outcomes among patients with early rapidly progressive rheumatoid arthritis. ED, eRPRA, HRU, MRI, ORs, TNF
74  2019 Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea. RA, TNF
75  2019 Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. RA, tsDMARD
76  2019 Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. AS, SF-36 PCS, TNFi
77  2019 Useful message in choosing optimal biological agents for patients with autoimmune arthritis. csDMARDs
78  2018 An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients. ADA, csDMARDs, DAS28-CRP, mHAQ-S, MTX, RA
79  2018 Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study. CDUS, IL-6, MCP-1, MIP-1b, RA, RAMRIS
80  2018 Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA). RA
81  2018 Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs. ---
82  2018 Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. CDAI, cDMARD, RA
83  2018 Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker. IFI44, IFI44L, IFN, MX1, RA, TNF-alpha, VERA
84  2018 Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. RA, SH
85  2018 Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. SES
86  2018 Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study. DAS28-CRP, RA, US
87  2018 Is there a relationship between spondyloarthritis and periodontitis? A case-control study. ASAS, SpA
88  2018 Predictive factors for structural remission using abatacept: Results from the ABROAD study. ABA, mTSS, OR, RA, St-REM
89  2018 Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing. MDA, PBS, PsA, RA
90  2018 Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. OACD
91  2018 Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. BiKeR, JIA, JuMBO
92  2018 Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. AS, OPAL, PsA, RA, TNFi, UnA
93  2018 [Change in rheumatic hip surgery]. ---
94  2017 Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. ACPA, CRRP, csDMARDs, DAS28-ESR, LDA, mTSS, RA, ROC
95  2017 Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study. HZ, IR, MTX, RA, REAL, TNFi
96  2017 Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD. ABA, IFX, MTX, RA, TCZ
97  2017 Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. ANZCTR, EULAR, IL-6, PD, RA, US, VEGF
98  2017 Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study. AS
99  2017 Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. ABA, AE, LORHEN, MTX, RA, TCZ, TNFi
100  2017 Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. CDAI, COMBO, cs, DAS28-ESR, EULAR, HAQ-DI, RA, SDAI